 OSAKA, Japan CAMBRIDGE, Mass.--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced that the Phase 3 PANTHER Pevonedistat-3001 study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival EFS. The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML an 